<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6DFB1100-7485-4E72-A435-75743D45CCB5"><gtr:id>6DFB1100-7485-4E72-A435-75743D45CCB5</gtr:id><gtr:name>Lentigen</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6DFB1100-7485-4E72-A435-75743D45CCB5"><gtr:id>6DFB1100-7485-4E72-A435-75743D45CCB5</gtr:id><gtr:name>Lentigen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FD6A1B62-365B-4829-97F2-46670524E531"><gtr:id>FD6A1B62-365B-4829-97F2-46670524E531</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Lever</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9805564"><gtr:id>51F95A5A-C225-4D4E-A526-9B2DF0D72847</gtr:id><gtr:title>Structural and functional studies in lentivirus RNA encapsidation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9805564</gtr:grantReference><gtr:abstractText>Despite remarkable recent advances in treatment of HIV/AIDS it is still one of the largest global health threats and the number of infected people is still rising. There are now a number of drugs which inhibit the virus but it can develop resistance to all of them. Combination therapy is the best and ideally drugs should block different stages of the virus life cycle. Finding new targets is vital. The virus packages its genetic material by allowing the genes which are in the form of RNA to fold into a special structure which distinguishes them from other RNAs in the cell. This structure is called a ?packaging signal?. We have been studying this structure and that of related viruses for several years. We plan to analyse this RNA structure further and to work out where in the cell the recognition process is occurring. We can then design agents to bind to the RNA in the critical region and block packaging of the genes into the virus. This will be a new drug target. If we block the genes entering the virus then an infected cell will release only protein containing, non infectious, virus-like particles which will boost the immune response in the patient.</gtr:abstractText><gtr:technicalSummary>Lentiviruses such as HIV, the causative agent of AIDS, are important pathogens in humans. They also have uniquely useful properties as gene delivery agents. Understanding the process by which the virus encapsidates its own RNA genome is critical to the development of safe lentiviral vectors and also provides a new therapeutic target for antiviral studies. We plan to extend our understanding of the sites and structures of lentiviral packaging signals in HIV-1, HIV-2 and SIV using structural techniques such as NMR crystallography and EM. We will pursue functional studies seeking the site in the cell at which RNA capture occurs using confocal methodologies and FRET. We will explore the interaction between packaging and translation and use our understanding of the critical structures involved and the site of the process within the cell to design antiviral therapeutics to inhibit encapsidation of RNA and hence viral replication.</gtr:technicalSummary><gtr:fund><gtr:end>2009-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1532865</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lentigen</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Licensing agreement</gtr:description><gtr:id>6A37E493-7EC6-42E4-B861-765928BADD52</gtr:id><gtr:impact>Lentigen have licensed our lentiviral vectors</gtr:impact><gtr:outcomeId>F1C6BD1DCB0-2</gtr:outcomeId><gtr:partnerContribution>Lentigen have licensed our lentiviral vectorsFunding for patent costs</gtr:partnerContribution><gtr:piContribution>Lentigen have licensed our lentiviral vectors</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lentigen</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Licensing agreement</gtr:description><gtr:id>CB7473AF-3B76-4E6F-9930-79EE12A23172</gtr:id><gtr:impact>Lentigen have licensed our lentiviral vectors</gtr:impact><gtr:outcomeId>F1C6BD1DCB0-1</gtr:outcomeId><gtr:partnerContribution>Lentigen have licensed our lentiviral vectorsFunding for patent costs</gtr:partnerContribution><gtr:piContribution>Lentigen have licensed our lentiviral vectors</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>8BAC3889-D23D-46F2-A4F9-CC00DD71AFDF</gtr:id><gtr:impact>Talk to 6th forms

Much interest</gtr:impact><gtr:outcomeId>62B068DE1DC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Milstein award</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3635AAEE-EDC2-4794-995F-A2CDF72D42C5</gtr:id><gtr:outcomeId>Ln75RiAcZSh0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>79976FB8-85E8-4F3E-9A13-FAA1F4A82F80</gtr:id><gtr:outcomeId>QDFNrg7y3ZW0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Important cis acting sequences in HIV vectors and novel cross packaging in chimeric vectors</gtr:description><gtr:grantRef>G9805564</gtr:grantRef><gtr:id>06D0065A-4B84-4C7F-BE50-7662E0327875</gtr:id><gtr:impact>patent costs covered

vectors licensed to Lentigen. Royalty payment in 2012 to University, Department of Medicine and Inventors as Lentigen completed Phase 1 clinical trial using lentiviral vectors based on the IPR</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>0094C32B386</gtr:outcomeId><gtr:patentId>EP1262554</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Novel lentiviral vectors</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>78611E72-D8C5-4446-8DA9-908384696254</gtr:id><gtr:title>Identification of unique reciprocal and non reciprocal cross packaging relationships between HIV-1, HIV-2 and SIV reveals an efficient SIV/HIV-2 lentiviral vector system with highly favourable features for in vivo testing and clinical usage.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c31c4dbe751477c6cad642ce4ead4cf4"><gtr:id>c31c4dbe751477c6cad642ce4ead4cf4</gtr:id><gtr:otherNames>Strappe PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>35FA34BB746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1081CF6-EC9F-4B2C-993F-89985A3BAF87</gtr:id><gtr:title>Inhibition of HIV-1 replication by oligonucleotide analogues directed to the packaging signal and trans-activating response region.</gtr:title><gtr:parentPublicationTitle>Antiviral chemistry &amp; chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7ac551b97440fb564f7271a324fadf3"><gtr:id>d7ac551b97440fb564f7271a324fadf3</gtr:id><gtr:otherNames>Brown DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0956-3202</gtr:issn><gtr:outcomeId>pm_12906_16_16542000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC888F14-F001-4D50-B7C5-0FB34DA3ECA7</gtr:id><gtr:title>Waking up the sleepers: HIV latency and reactivation.</gtr:title><gtr:parentPublicationTitle>Journal of the Formosan Medical Association = Taiwan yi zhi</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a64c125c12f8d154f93b9d59d6f280c"><gtr:id>5a64c125c12f8d154f93b9d59d6f280c</gtr:id><gtr:otherNames>Mok HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0929-6646</gtr:issn><gtr:outcomeId>pm_12906_16_19129050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1702810D-91F8-4478-8323-80F744D199C8</gtr:id><gtr:title>Delivery of a lentiviral vector in a Pluronic F127 gel to cells of the central nervous system.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c31c4dbe751477c6cad642ce4ead4cf4"><gtr:id>c31c4dbe751477c6cad642ce4ead4cf4</gtr:id><gtr:otherNames>Strappe PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0939-6411</gtr:issn><gtr:outcomeId>C4870AF6791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E74B1738-0CB4-4CAA-BB36-041391BD7799</gtr:id><gtr:title>Dimerisation of HIV-2 genomic RNA is linked to efficient RNA packaging, normal particle maturation and viral infectivity.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bc884aa239160a2d44f740d3c8a61a8"><gtr:id>4bc884aa239160a2d44f740d3c8a61a8</gtr:id><gtr:otherNames>L'Hernault A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>8A0095E80C5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEE4C0F7-562E-4517-AF40-1F9F2EB9A563</gtr:id><gtr:title>The secondary structure of the 5' end of the FIV genome reveals a long-range interaction between R/U5 and gag sequences, and a large, stable stem-loop.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/604f916efba5cb5af8a2f429da5b435c"><gtr:id>604f916efba5cb5af8a2f429da5b435c</gtr:id><gtr:otherNames>Kenyon JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn><gtr:outcomeId>pm_12906_16_18974279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BCE5153-0914-451D-A19E-EB00EF4AB194</gtr:id><gtr:title>Stable gene expression occurs from a minority of integrated HIV-1-based vectors: transcriptional silencing is present in the majority.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a64c125c12f8d154f93b9d59d6f280c"><gtr:id>5a64c125c12f8d154f93b9d59d6f280c</gtr:id><gtr:otherNames>Mok HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>pm_12906_16_17330088</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1C09E9-E025-4477-B82D-48D089A7B24E</gtr:id><gtr:title>Human immunodeficiency virus type 1 Gag polyprotein modulates its own translation.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6ea6f37c2577e51beb5cc86b46e7df0"><gtr:id>d6ea6f37c2577e51beb5cc86b46e7df0</gtr:id><gtr:otherNames>Anderson EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D75527C5DEF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F076DB0C-8108-4072-8442-4F6AD2F478FE</gtr:id><gtr:title>HIV-1 Gag-RNA interaction occurs at a perinuclear/centrosomal site; analysis by confocal microscopy and FRET.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bdc40f0f8c6b621c5ccc76e7dcc36da"><gtr:id>4bdc40f0f8c6b621c5ccc76e7dcc36da</gtr:id><gtr:otherNames>Poole E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>43CAE94F909</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9FC61FA-CEB3-4E19-8AB1-C49867DBE486</gtr:id><gtr:title>Steric block high affinity oligonucleotide analogues: a new tool for mapping RNA-protein binding sites.</gtr:title><gtr:parentPublicationTitle>Nucleosides, nucleotides &amp; nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57ce83deb2398a489b9544f192ed396b"><gtr:id>57ce83deb2398a489b9544f192ed396b</gtr:id><gtr:otherNames>Brown D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-7770</gtr:issn><gtr:outcomeId>DAB7DC4E682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A95A85F-4596-43A6-BB5A-CDBF9E75505E</gtr:id><gtr:title>Mutation of the Rev-binding loop in the human immunodeficiency virus 1 leader causes a replication defect characterized by altered RNA trafficking and packaging.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cddb88e729786c1db4f95eab591264a4"><gtr:id>cddb88e729786c1db4f95eab591264a4</gtr:id><gtr:otherNames>Greatorex JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>A2D9B2527F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>947CD874-34CE-4037-A7E2-0C67FD63718E</gtr:id><gtr:title>Rev regulates translation of human immunodeficiency virus type 1 RNAs.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1967f1ef6807f4bedadc0b6799a69e9a"><gtr:id>1967f1ef6807f4bedadc0b6799a69e9a</gtr:id><gtr:otherNames>Groom HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>D9ED990B170</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F79FAADF-C7FE-40ED-90D6-D0F3072D93A1</gtr:id><gtr:title>Replication of human immunodeficiency virus type 1 from entry to exit.</gtr:title><gtr:parentPublicationTitle>International journal of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17df4f22aab0306b360c42f283f05f57"><gtr:id>17df4f22aab0306b360c42f283f05f57</gtr:id><gtr:otherNames>Lever AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0925-5710</gtr:issn><gtr:outcomeId>pm_12906_16_16867898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34341034-BCA8-40D4-AEEF-3909EB576A5C</gtr:id><gtr:title>A method to estimate the efficiency of gene expression from an integrated retroviral vector.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a64c125c12f8d154f93b9d59d6f280c"><gtr:id>5a64c125c12f8d154f93b9d59d6f280c</gtr:id><gtr:otherNames>Mok HP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>pm_12906_16_16916442</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9805564</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>